EAM Investors’s Travere Therapeutics TVTX Stock Holding History

EAM Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-109,404	Closed	-$4.18M	–	377
2025 Q4	$4.18M	Buy	+109,404	New	+$3.56M	0.47%	113
2025 Q2	–	Sell	-150,286	Closed	-$2.69M	–	351
2025 Q1	$2.69M	Buy	+150,286	New	+$3.05M	0.47%	108
2016 Q4	–	Sell	-31,611	Closed	-$707K	–	367
2016 Q3	$707K	Buy	+31,611	New	+$602K	0.1%	285
2015 Q3	–	Sell	-43,616	Closed	-$1.45M	–	341
2015 Q2	$1.45M	Buy	+43,616	New	+$1.19M	0.17%	234

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM Investors's TVTX Position: Q1 2026 in Review

EAM Investors sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 109,404 shares — an estimated $4.18M sold.

EAM Investors first reported a position in TVTX in Q2 2015 and held it in 4 quarters. The position peaked at $4.18M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

EAM Investors reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 109,404 Travere Therapeutics shares in Q1 2026, an estimated $4.18M.
EAM Investors first reported a position in Travere Therapeutics in Q2 2015 and held it in 4 quarters.
EAM Investors's Travere Therapeutics position peaked at $4.18M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.